ASPRE

Combined Multi-marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention

Coordinatore	FETAL MEDICINE FOUNDATION    more  Organization address address: HARLEY STREET 137 city: LONDON postcode: W1G 6BG contact info Titolo: Mr. Nome: Thanos Cognome: Kotsis Email: send email Telefono: +44 2070340370 Fax: +44 2070343071
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	7˙638˙094 €
EC contributo	5˙839˙800 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-05-01   -   2016-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FETAL MEDICINE FOUNDATION  Organization address address: HARLEY STREET 137 city: LONDON postcode: W1G 6BG contact info Titolo: Mr. Nome: Thanos Cognome: Kotsis Email: send email Telefono: +44 2070340370 Fax: +44 2070343071	UK (LONDON)	coordinator	2˙275˙156.00
2	HY LABORATORIES LTD  Organization address address: MENACHEM PLAUT STR PARK TAMAR 6 city: REHOVOT postcode: 76326 contact info Titolo: Mr. Nome: Winkler Cognome: Or Email: send email Telefono: +972 89366475 Fax: +972 89366474	IL (REHOVOT)	participant	2˙013˙547.00
3	ASTRAIA SOFTWARE GMBH  Organization address address: Occam Strasse 20 city: MUNCHEN postcode: 80802 contact info Titolo: Ms. Nome: Angela Cognome: Döring Email: send email Telefono: +49 89 127 1147 0 Fax: +49 89 127 114 17	DE (MUNCHEN)	participant	567˙800.00
4	Wallac Oy  Organization address address: Mustionkatu 6 city: Turku postcode: 20750 contact info Titolo: Ms. Nome: Tarja Cognome: Ahola Email: send email Telefono: +358 22678111 Fax: +358 22678357	FI (Turku)	participant	509˙604.00
5	HANANJA EHF  Organization address address: AFLAGRANDA 7 city: REYKJAVIK postcode: 107 contact info Titolo: Ms. Nome: Kristin Linda Cognome: Ragnarsdottir Email: send email Telefono: +354 898 0319 Fax: +354 525 4071	IS (REYKJAVIK)	participant	473˙693.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Project ASPRE is a commercially led development project that aims to boost translation of the results of PREGENESYS (FP6 EU #37244) into effective applications for prenatal care. PREGENESYS has identified several biomarkers for early (11-13 weeks’ gestation) and effective identification of pregnancies at high risk of developing pre-eclampsia (PE). This disorder affects 2-8% of pregnant women and is a major cause of short- and long-term maternal and perinatal morbidity and mortality. Studies under PREGENESYS using in-vitro research methods suggested that aspirin is the most promising agent for preventing PE. Evidence from small clinical studies has indicated that prophylactic use of low-dose aspirin starting before 16 weeks’ gestation can potentially halve the PE prevalence and its associated complications. Objectives: Widespread clinical implementation of a strategy of screening and prevention of PE: (1) Reduce the prevalence of PE requiring delivery before 37 weeks (preterm PE) by at least 50%, (2) Demonstrate through a large multicentre screening and prevention study the acceptability, uptake and efficacy of first trimester multi-parameter screening of preterm PE and its preventative treatment with aspirin, (3) Develop affordable, automated and reliable methods for high throughput measurement of biomarkers and commercial platforms for PE risk assessment software, (4) Develop management protocols for high risk and low risk pregnancies for PE, (5) Improve education and training of healthcare professionals involved in pregnancy care, (6) Conduct the dissemination and training required to drive clinical acceptance and adoption of multi-parameter PE screening and aspirin treatment. Expected results and impact: Generating a market demand for SME-based newly developed products for PE screening and prevention, including machines, kits and software, thereby transforming research success into economic growth for SMEs and upholding European leadership in perinatal care.'

Introduzione (Teaser)

Pre-eclampsia (PE) is a major cause of short- and long-term maternal and perinatal morbidity and mortality. An effective screening and treatment programme would provide clear health and social benefits for pregnant women.